Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors

Journal of Alzheimer's Disease

Volumn 39, Issue 2, 2014, Pages 423-440

  Darreh Shori, Taher ^a   Hosseini, Sharokh Makvand ^a,c   Nordberg, Agneta ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SEMNAN UNIVERSITY   (Iran)

Author keywords

Add on therapy; Alzheimer's disease; carbamylating ChEIs; cholinesterase inhibitors (ChEIs); donepezil; peripheral anionic site; phenserine; rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; DONEPEZIL; PHENSERINE; PLACEBO;

ADD ON THERAPY; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADD-ON THERAPY; ALZHEIMER'S DISEASE; CARBAMYLATING CHEIS; CHOLINESTERASE INHIBITORS (CHEIS); DONEPEZIL; PERIPHERAL ANIONIC SITE; PHENSERINE; RIVASTIGMINE;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BLOTTING, WESTERN; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FLUORESCENCE; FOLLOW-UP STUDIES; HUMANS; INDANS; PHYSOSTIGMINE; PIPERIDINES; THIAZOLES; TIME FACTORS;

EID: 84893960039     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130845     Document Type: Article

References (80)

1. Fratiglioni L, Launer LJ, Andersen K, Breteler MMB, Copeland JRM, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A, Grp NDER (2000) Incidence of dementia and major subtypes in Europe:Acollaborative study of population-based cohorts. Neurology 54, S10-S15.
2. Shanks M, Kivipelto M, Bullock R, Lane R (2009) Cholinesterase inhibition: Is there evidence for diseasemodifying effects? Curr Med Res Opin 25, 2439-2446.
3. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, SmithAD(2013) Preventing Alzheimer's diseaserelated gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110, 9523-9528.
4. Kryger G, Silman I, Sussman JL (1999) Structure of acetylcholinesterase complexed with E2020 (Aricept): Implications for the design of new anti-Alzheimer drugs. Structure 7, 297-307.
5. Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y (2000) Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 7, 303-339.
6. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, Soreq H, Hellstrom-Lindahl E, Nordberg A (2002) Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59, 563-572.
7. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 318, 633-638.
8. Darreh-Shori T, Soininen H (2010) Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: A review of recent clinical studies. Curr Alzheimer Res 7, 67-73.
9. Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N, Minthon L, Nordberg A (2006) Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 113, 1791-1801.
10. Darreh-Shori T, Hellstrom-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H, Nordberg A (2004) Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem 88, 1102-1113.
11. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Larksater M, Winblad B, Zetterberg H, Blennow K, Langstrom B, Nordberg A (2008) Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63, 621-631.
12. Layer PG, Allebrandt K, Andermann P, Bodur E, Boopathy R, Bytyqi AH, Paraoanu LE (2005) On the multifunctionality of cholinesterases. Chem Biol Interact 157, 37-41.
13. Mangialasche F, Solomon A,Winblad B, Mecocci P, Kivipelto M(2010) Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 9, 702-716.
14. Corbett A, Ballard C (2012) Newand emerging treatments for Alzheimer's disease. Expert Opin Emerg Drugs 17, 147-156.
15. Mesulam M, Carson K, Price B, Geula C (1992) Cholinesterases in the amyloid angiopathy of Alzheimer's disease. Ann Neurol 31, 565-569.
16. Mesulam MM, Geula C (1994) Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36, 722-727.
17. Geula C, Mesulam MM (1995) Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 9(Suppl 2), 23-28.
18. Geula C, Greenberg BD, MesulamMM(1994) Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid. Brain Res 644, 327-330.
19. Wright CI, Geula C, Mesulam MM (1993) Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 34, 373-384.
20. Inestrosa NC, Dinamarca MC, Alvarez A (2008) Amyloidcholinesterase interactions-Implications for Alzheimer's disease. FEBS J 275, 625-632.
21. Kar S, Issa AM, Seto D, Auld DS, Collier B, Quirion R (1998) Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem 70, 2179-2187.
22. Joseph R, Han E (1992) Amyloid beta-protein fragment 25-35 causes activation of cytoplasmic calcium in neurons. Biochem Biophys Res Commun 184, 1441-1447.
23. Colom LV, Diaz ME, Beers DR, Neely A, Xie WJ, Appel SH (1998) Role of potassium channels in amyloid-induced cell death. J Neurochem 70, 1925-1934.
24. Mark RJ, Hensley K, Butterfield DA, Mattson MP (1995) Amyloid beta-peptide impairs ion-motive ATPase activities: Evidence for a role in loss of neuronal Ca2+homeostasis and cell death. J Neurosci 15, 6239-6249.
25. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H (2006) Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A 103, 8628-8633.
26. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16, 881-891.
27. ReesT, Hammond PI, Soreq H,Younkin S, Brimijoin S (2003) Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 24, 777-787.
28. Rees TM, Berson A, Sklan EH, Younkin L, Younkin S, Brimijoin S, Soreq H (2005) Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res 2, 291-300.
29. Sberna G, Saez-Valero J, Li QX, Czech C, Beyreuther K, Masters CL, McLean CA, Small DH (1998) Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. J Neurochem 71, 723-731.
30. Saez-Valero J, de Ceballos ML, Small DH, de Felipe C (2002) Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid betapeptide. Neurosci Lett 325, 199-202.
31. Sussman JL, Harel M, FrolowF, Oefner C, Goldman A, Toker L, Silman I (1991) Atomic-structure of acetylcholinesterase fromTorpedo-californica-a prototypic acetylcholine-binding protein. Science 253, 872-879.
32. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH, Dajas F, Gentry MK, Doctor BP, De Mello FG, Inestrosa NC (1998) Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 18, 3213-3223.
33. De FerrariGV, CanalesMA,Shin I,Weiner LM, Silman I, Inestrosa NC (2001) A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 40, 10447-10457.
34. Johnson G, Moore SW (2006) The peripheral anionic site of acetylcholinesterase: Structure, functions and potential role in rational drug design. Curr Pharm Des 12, 217-225.
35. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I (2002) Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41, 3555-3564.
36. Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) betaamyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol 65, 407-416.
37. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Larksater M, Winblad B, Zetterberg H, Blennow K, Langstrom B, Nordberg A (2008) Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63, 621-631.
38. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
39. Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
40. Andreasen N, Blennow K, Sjodin C, Winblad B, Svardsudd K (1999) Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Pitea Dementia Project. Neuroepidemiology 18, 144-155.
41. Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A (2006) Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis 24, 326-333.
42. Naiki H, Nakakuki K (1996) First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab Invest 74, 374-383.
43. LeVine H, 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309, 274-284.
44. Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, Eriksson B, Langstrom B, Nordberg A (2008) Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 29, 168-184.
45. Carvajal FJ, Inestrosa NC (2011) Interactions of AChE with Abeta aggregates in Alzheimer's brain: Therapeutic relevance of IDN 5706. Front Mol Neurosci 4, 19.
46. Darreh-Shori T, Modiri N, Lahaut P, Nordberg A (2009) Apolipoprotein E and butyrylcholinesterase synergistically promote Aβ peptides oligomerization. Alzheimers Dement 5(Suppl), P225.
47. Darreh-Shori T, Modiri N, Nordberg A (2009) ApoE and amyloid beta deflate the cholinergic neurotransmission by boosting the activity and stability of cholinesterases in the brain. Alzheimers Dement 5(Suppl), P305.
48. Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Langstrom B, NordbergA(2011) Differential levels of apolipoprotein E and butyrylcholinesterase showstrong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging 32, 2320 e2315-2332.
49. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A (2011) The apolipoprotein E epsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging 32, 1236-1248.
50. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, BucklesV, OliverA, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
51. Darreh-Shori T, Vijayaraghavan S, Aeinehband S, Piehl F, Lindblom RP, Nilsson B, Ekdahl KN, Langstrom B, Almkvist O, Nordberg A (2013) Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiol Aging 34, 2465-2481.
52. Vijayaraghavan S, Karami A, Aeinehband S, Behbahani H, Grandien A, Nilsson B, Ekdahl KN, Lindblom RP, Piehl F, Darreh-Shori T (2013) Regulated extracellular choline acetyltransferase activity-the plausible missing link of the distant action of acetylcholine in the cholinergic anti-inflammatory pathway. PLoS One 8, e65936.
53. Darreh-Shori T, Hellstrom-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H, Nordberg A (2004) Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem 88, 1102-1113.
54. NordbergA, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, Lane R (2009) Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6, 4-14.
55. Chippendale TJ, Cotman CW, Kozar MD, Lynch GS (1974) Analysis of acetylcholinesterase synthesis and transport in the rat hippocampus: Recovery of acetylcholinesterase activity in the septum and hippocampus after administration of diisopropylfluorophosphate. Brain Res 81, 485-496.
56. Kasprzak H, Salpeter MM (1985) Recovery of acetylcholinesterase at intact neuromuscular junctions after in vivo inactivation with di- isopropylfluorophosphate. J Neurosci 5, 951-955.
57. Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR, Jr, Canfield CJ, Burford RG (2005) Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2, 483-492.
58. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I (2002) Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41, 3555-3564.
59. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Langstrom B, Nordberg A (2007) Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 191, 1005-1014.
60. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, Ringheim A, Eriksson B, Blomquist G, Langstrom B, Nordberg A (2008) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 29, 1204-1217.
61. Inestrosa NC, Alvarez A, Calderon F (1996) Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments. Mol Psychiatry 1, 359-361.
62. Lane RM, He Y (2013) Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. Alzheimers Dement 9, e1-73.
63. Venneri A, Lane R (2009) Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport 20, 285-288.
64. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21, 1317-1327.
65. Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R (2006) Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewybody pathology. Curr Med Res Opin 22, 49-59.
66. Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R (2006) Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 22, 483-494.
67. Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R (2006) Effect of butyryl cholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics 16, 771-774.
68. Darreh-Shori T, Vijayaraghavan S, Aeinehband S, Piehl F, Lindblom RP, Nilsson B, Ekdahl KN, Langstrom B, Almkvist O, Nordberg A (2013) Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiol Aging 34, 2465-2481.
69. Karami A, Eyjólfsdóttir H, Vijayaraghavan S, Kadir A, Linderothbd B, Göran Lindbd G, Andreasen N, Anders Wall, Ake Seiger, Per Almqvist, Lars Wahlberg, Agneta Nordberg, Taher Darreh-Shori, Eriksdotter M (2012) Cell therapy with NGF in patients with Alzheimer's disease: Changes in CSF cholinergic markers. Eur J Neurol 19(Suppl 1), 91.
70. Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M (2013) A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. Prim Care Companion CNS Disord 15, pii: PCC.12r01412.
71. Darreh-Shori T, Jelic V (2010) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf 9, 167-176.
72. Camps P, Formosa X, Galdeano C, Gomez T, Munoz-Torrero D, Scarpellini M, Viayna E, Badia A, Clos MV, Camins A, Pallas M, Bartolini M, Mancini F, Andrisano V, Estelrich J, Lizondo M, Bidon-Chanal A, Luque FJ (2008) Novel donepezil-based inhibitors of acetyl-and butyrylcholinesterase and acetylcholinesterase-induced betaamyloid aggregation. J Med Chem 51, 3588-3598.
73. Nunes-Tavares N, Santos LE, Stutz B, Brito-Moreira J, Klein WL, Ferreira ST, de Mello FG (2012) Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-beta peptide oligomers. J Biol Chem 287, 19377-19385.
74. Dobransky T, Brewer D, Lajoie G, Rylett RJ (2003) Phosphorylation of 69-kDa choline acetyltransferase at threonine 456 in response to amyloid-beta peptide 1-42. J Biol Chem 278, 5883-5893.
75. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide:Acase report. Nat Med 9, 448-452.
76. Boche D, Denham N, Holmes C, Nicoll JA (2010) Neuropathology after active Abeta42 immunotherapy: Implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120, 369-384.
77. Meyer-Luehmann M, Mora JR, Mielke M, Spires-Jones TL, de Calignon A, von Andrian UH, Hyman BT (2011) T cell mediated cerebral hemorrhages and microhemorrhages during passive Abeta immunization in APPPS1 transgenic mice. Mol Neurodegener 6, 22.
78. Ratia M, Gimenez-Llort L, Camps P, Munoz-Torrero D, Perez B, Clos MV, Badia A (2013) Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD). Neurodegener Dis 11, 129-140.
79. Viayna E, Gomez T, Galdeano C, Ramirez L, Ratia M, Badia A, Clos MV, Verdaguer E, Junyent F, Camins A, Pallas M, Bartolini M, Mancini F, Andrisano V, Arce MP, Rodriguez-Franco MI, Bidon-Chanal A, Luque FJ, Camps P, Munoz-Torrero D (2010) Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates. ChemMedChem 5, 1855-1870.
80. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK (2005) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2, 281-290.